Cordyceps Sunshine Biotech Holdings Co Ltd Financials
This page shows Cordyceps Sunshine Biotech Holdings Co Ltd (RAJAF) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores
Cordyceps Sunshine Biotech Holdings Co Ltd has an operating margin of -14.7%, meaning the company retains $-15 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is down from 25.8% the prior year.
Cordyceps Sunshine Biotech Holdings Co Ltd's revenue surged 42.0% year-over-year to $1.3M, reflecting rapid business expansion. This strong growth earns a score of 100/100.
Cordyceps Sunshine Biotech Holdings Co Ltd's current ratio of 0.12 means current assets barely cover short-term liabilities. This tight liquidity results in a low score of 0/100, which could limit financial flexibility.
While Cordyceps Sunshine Biotech Holdings Co Ltd generated $312K in operating cash flow, capex of $349K consumed most of it, leaving -$37K in free cash flow. This results in a low score of 18/100, reflecting heavy capital investment rather than weak cash generation.
Cordyceps Sunshine Biotech Holdings Co Ltd passes 6 of 9 financial strength tests. 2 of 4 profitability signals pass, all 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.
For every $1 of reported earnings, Cordyceps Sunshine Biotech Holdings Co Ltd generates $-1.38 in operating cash flow ($312K OCF vs -$226K net income). This mixed ratio suggests some earnings may rely on non-cash accounting items.
Key Financial Metrics
Earnings & Revenue
Cordyceps Sunshine Biotech Holdings Co Ltd generated $1.3M in revenue in fiscal year 2024. This represents an increase of 42.0% from the prior year.
Cordyceps Sunshine Biotech Holdings Co Ltd's EBITDA was $223K in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 21.5% from the prior year.
Cordyceps Sunshine Biotech Holdings Co Ltd reported -$226K in net income in fiscal year 2024. This represents a decrease of 130.1% from the prior year.
Cordyceps Sunshine Biotech Holdings Co Ltd earned $0.00 per diluted share (EPS) in fiscal year 2024. This represents a decrease of 100.0% from the prior year.
Cash & Balance Sheet
Cordyceps Sunshine Biotech Holdings Co Ltd generated -$37K in free cash flow in fiscal year 2024, representing cash available after capex. This represents a decrease of 192.5% from the prior year.
Cordyceps Sunshine Biotech Holdings Co Ltd held $37K in cash against $0 in long-term debt as of fiscal year 2024.
Cordyceps Sunshine Biotech Holdings Co Ltd had 111M shares outstanding in fiscal year 2024. This represents an increase of 0.0% from the prior year.
Margins & Returns
Cordyceps Sunshine Biotech Holdings Co Ltd's gross margin was 42.6% in fiscal year 2024, indicating the percentage of revenue retained after direct costs. This is down 44.3 percentage points from the prior year.
Cordyceps Sunshine Biotech Holdings Co Ltd's operating margin was -14.7% in fiscal year 2024, reflecting core business profitability. This is down 40.5 percentage points from the prior year.
Cordyceps Sunshine Biotech Holdings Co Ltd's net profit margin was -18.1% in fiscal year 2024, showing the share of revenue converted to profit. This is down 103.2 percentage points from the prior year.
Capital Allocation
Cordyceps Sunshine Biotech Holdings Co Ltd invested $349K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents an increase of 9.3% from the prior year.
RAJAF Income Statement
| Metric | Q4'24 | Q4'23 | Q3'23 | Q4'22 | Q4'21 | Q4'20 |
|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A Expenses | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Income | N/A | N/A | N/A | N/A | N/A | N/A |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS (Diluted) | N/A | N/A | N/A | N/A | N/A | N/A |
RAJAF Balance Sheet
| Metric | Q4'24 | Q4'23 | Q3'23 | Q4'22 | Q4'21 | Q4'20 |
|---|---|---|---|---|---|---|
| Total Assets | $4.6M+37.9% | $3.4M+86.4% | $1.8M-14.6% | $2.1M-35.5% | $3.3M+15.5% | $2.8M |
| Current Assets | $602K+83.9% | $327K+527.6% | $52K-89.6% | $502K-55.6% | $1.1M+19.2% | $949K |
| Cash & Equivalents | $37K+61.4% | $23K+36.6% | $17K+155.1% | $7K-93.4% | $100K+33806.1% | $294 |
| Inventory | N/A | N/A | $4K-98.6% | $314K-34.7% | $480K-29.9% | $685K |
| Accounts Receivable | $305 | N/A | N/A | $150K-58.2% | $358K | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $5.0M+42.7% | $3.5M+76.9% | $2.0M-35.2% | $3.1M-13.6% | $3.5M+24.7% | $2.8M |
| Current Liabilities | $5.0M+68.1% | $3.0M+102.4% | $1.5M-41.9% | $2.5M-13.7% | $2.9M+21.1% | $2.4M |
| Long-Term Debt | N/A | $431K+325.4% | $101K-75.5% | $414K | N/A | N/A |
| Total Equity | -$376K-147.4% | -$152K+17.0% | -$183K+80.8% | -$951K-244.9% | -$276K-2052.8% | -$13K |
| Retained Earnings | -$699K-47.8% | -$473K+0.9% | -$477K+61.0% | -$1.2M-142.7% | -$504K-3643.6% | -$13K |
RAJAF Cash Flow Statement
| Metric | Q4'24 | Q4'23 | Q3'23 | Q4'22 | Q4'21 | Q4'20 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | N/A | -$1.2M | N/A | -$111K | N/A | N/A |
| Capital Expenditures | N/A | -$1.2M | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | -$2.5M | N/A | N/A | N/A | N/A |
| Investing Cash Flow | N/A | $1.2M | N/A | -$1K | N/A | N/A |
| Financing Cash Flow | N/A | $48K | N/A | $7K | N/A | N/A |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A |
RAJAF Financial Ratios
| Metric | Q4'24 | Q4'23 | Q3'23 | Q4'22 | Q4'21 | Q4'20 |
|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | N/A | N/A | N/A | N/A | N/A | N/A |
| Current Ratio | 0.12+0.0 | 0.11+0.1 | 0.04-0.2 | 0.20-0.2 | 0.390.0 | 0.39 |
| Debt-to-Equity | -13.31-10.5 | -2.84-2.3 | -0.55-0.1 | -0.44+12.4 | -12.83+208.7 | -221.55 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A |
Note: Shareholder equity is negative (-$376K), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.12), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Frequently Asked Questions
What is Cordyceps Sunshine Biotech Holdings Co Ltd's annual revenue?
Cordyceps Sunshine Biotech Holdings Co Ltd (RAJAF) reported $1.3M in total revenue for fiscal year 2024. This represents a 42.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Cordyceps Sunshine Biotech Holdings Co Ltd's revenue growing?
Cordyceps Sunshine Biotech Holdings Co Ltd (RAJAF) revenue grew by 42% year-over-year, from $883K to $1.3M in fiscal year 2024.
Is Cordyceps Sunshine Biotech Holdings Co Ltd profitable?
No, Cordyceps Sunshine Biotech Holdings Co Ltd (RAJAF) reported a net income of -$226K in fiscal year 2024, with a net profit margin of -18.1%.
What is Cordyceps Sunshine Biotech Holdings Co Ltd's EBITDA?
Cordyceps Sunshine Biotech Holdings Co Ltd (RAJAF) had EBITDA of $223K in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Cordyceps Sunshine Biotech Holdings Co Ltd's gross margin?
Cordyceps Sunshine Biotech Holdings Co Ltd (RAJAF) had a gross margin of 42.6% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.
What is Cordyceps Sunshine Biotech Holdings Co Ltd's operating margin?
Cordyceps Sunshine Biotech Holdings Co Ltd (RAJAF) had an operating margin of -14.7% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is Cordyceps Sunshine Biotech Holdings Co Ltd's net profit margin?
Cordyceps Sunshine Biotech Holdings Co Ltd (RAJAF) had a net profit margin of -18.1% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is Cordyceps Sunshine Biotech Holdings Co Ltd's free cash flow?
Cordyceps Sunshine Biotech Holdings Co Ltd (RAJAF) generated -$37K in free cash flow during fiscal year 2024. This represents a -192.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Cordyceps Sunshine Biotech Holdings Co Ltd's operating cash flow?
Cordyceps Sunshine Biotech Holdings Co Ltd (RAJAF) generated $312K in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Cordyceps Sunshine Biotech Holdings Co Ltd's total assets?
Cordyceps Sunshine Biotech Holdings Co Ltd (RAJAF) had $4.6M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Cordyceps Sunshine Biotech Holdings Co Ltd's capital expenditures?
Cordyceps Sunshine Biotech Holdings Co Ltd (RAJAF) invested $349K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
What is Cordyceps Sunshine Biotech Holdings Co Ltd's current ratio?
Cordyceps Sunshine Biotech Holdings Co Ltd (RAJAF) had a current ratio of 0.12 as of fiscal year 2024, which is below 1.0, which may suggest potential liquidity concerns.
What is Cordyceps Sunshine Biotech Holdings Co Ltd's debt-to-equity ratio?
Cordyceps Sunshine Biotech Holdings Co Ltd (RAJAF) had a debt-to-equity ratio of -13.31 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Cordyceps Sunshine Biotech Holdings Co Ltd's return on assets (ROA)?
Cordyceps Sunshine Biotech Holdings Co Ltd (RAJAF) had a return on assets of -4.9% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
Why is Cordyceps Sunshine Biotech Holdings Co Ltd's debt-to-equity ratio negative or unusual?
Cordyceps Sunshine Biotech Holdings Co Ltd (RAJAF) has negative shareholder equity of -$376K as of fiscal year 2024, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Cordyceps Sunshine Biotech Holdings Co Ltd's Piotroski F-Score?
Cordyceps Sunshine Biotech Holdings Co Ltd (RAJAF) has a Piotroski F-Score of 6 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Cordyceps Sunshine Biotech Holdings Co Ltd's earnings high quality?
Cordyceps Sunshine Biotech Holdings Co Ltd (RAJAF) has an earnings quality ratio of -1.38x, considered mixed quality. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Cordyceps Sunshine Biotech Holdings Co Ltd?
Cordyceps Sunshine Biotech Holdings Co Ltd (RAJAF) scores 29 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.